VRNA
VRNA
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $75.142M ▲ | $61.984M ▼ | $8.685M ▲ | 11.558% ▲ | $0.1 ▲ | $9.907M ▲ |
| Q1-2025 | $59.027M ▲ | $64.376M ▲ | $-12.632M ▲ | -21.4% ▲ | $-0.15 ▲ | $-7.758M ▲ |
| Q4-2024 | $29.278M ▲ | $42.297M ▲ | $-27.019M ▲ | -92.285% ▲ | $-0.33 ▲ | $-13.997M ▲ |
| Q3-2024 | $4.206M ▲ | $34.217M ▼ | $-32.133M ▲ | -763.905% ▼ | $-0.39 ▲ | $-29.012M ▲ |
| Q2-2024 | $0 | $54.127M | $-56.035M | 0% | $-0.69 | $-53.244M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $438.016M ▲ | $572.871M ▲ | $294.598M ▼ | $278.273M ▲ |
| Q1-2025 | $401.415M ▲ | $525.936M ▲ | $299.341M ▲ | $226.595M ▲ |
| Q4-2024 | $399.757M ▲ | $474.242M ▲ | $269.683M ▲ | $204.559M ▲ |
| Q3-2024 | $336.04M ▼ | $381.818M ▼ | $251.327M ▼ | $130.491M ▼ |
| Q2-2024 | $404.599M | $434.123M | $265.849M | $168.274M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $11.921M ▲ | $30.561M ▲ | $0 ▲ | $4.943M ▼ | $36.601M ▲ | $30.561M ▲ |
| Q1-2025 | $-16.382M ▲ | $-11.561M ▲ | $-535K | $13.457M ▼ | $1.658M ▼ | $-11.561M ▲ |
| Q4-2024 | $-33.827M ▲ | $-28.836M ▲ | $-535K ▼ | $94.157M ▲ | $63.717M ▲ | $-29.371M ▲ |
| Q3-2024 | $-42.962M ▲ | $-62.655M ▼ | $13 ▲ | $-7.087M ▼ | $-68.559M ▼ | $-62.655M ▼ |
| Q2-2024 | $-70.914M | $-16.756M | $-29.023K | $166.518M | $149.717M | $-16.785M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 |
|---|---|---|
 Product | $70.00M ▲ | $100.00M ▲ |
 Product and Service Other | $10.00M ▲ | $0 ▼ |
About Verona Pharma plc
https://www.veronapharma.comVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $75.142M ▲ | $61.984M ▼ | $8.685M ▲ | 11.558% ▲ | $0.1 ▲ | $9.907M ▲ |
| Q1-2025 | $59.027M ▲ | $64.376M ▲ | $-12.632M ▲ | -21.4% ▲ | $-0.15 ▲ | $-7.758M ▲ |
| Q4-2024 | $29.278M ▲ | $42.297M ▲ | $-27.019M ▲ | -92.285% ▲ | $-0.33 ▲ | $-13.997M ▲ |
| Q3-2024 | $4.206M ▲ | $34.217M ▼ | $-32.133M ▲ | -763.905% ▼ | $-0.39 ▲ | $-29.012M ▲ |
| Q2-2024 | $0 | $54.127M | $-56.035M | 0% | $-0.69 | $-53.244M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $438.016M ▲ | $572.871M ▲ | $294.598M ▼ | $278.273M ▲ |
| Q1-2025 | $401.415M ▲ | $525.936M ▲ | $299.341M ▲ | $226.595M ▲ |
| Q4-2024 | $399.757M ▲ | $474.242M ▲ | $269.683M ▲ | $204.559M ▲ |
| Q3-2024 | $336.04M ▼ | $381.818M ▼ | $251.327M ▼ | $130.491M ▼ |
| Q2-2024 | $404.599M | $434.123M | $265.849M | $168.274M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $11.921M ▲ | $30.561M ▲ | $0 ▲ | $4.943M ▼ | $36.601M ▲ | $30.561M ▲ |
| Q1-2025 | $-16.382M ▲ | $-11.561M ▲ | $-535K | $13.457M ▼ | $1.658M ▼ | $-11.561M ▲ |
| Q4-2024 | $-33.827M ▲ | $-28.836M ▲ | $-535K ▼ | $94.157M ▲ | $63.717M ▲ | $-29.371M ▲ |
| Q3-2024 | $-42.962M ▲ | $-62.655M ▼ | $13 ▲ | $-7.087M ▼ | $-68.559M ▼ | $-62.655M ▼ |
| Q2-2024 | $-70.914M | $-16.756M | $-29.023K | $166.518M | $149.717M | $-16.785M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 |
|---|---|---|
| Product | $70.00M ▲ | $100.00M ▲ |
| Product and Service Other | $10.00M ▲ | $0 ▼ |
CEO
David S. Zaccardelli
Compensation Summary
(Year 2024)
CEO
David S. Zaccardelli
Compensation Summary
(Year 2024)
Most Recent Analyst Grades
Roth Capital
Buy
Truist Securities
Buy
Piper Sandler
Overweight
Cantor Fitzgerald
Overweight
Wells Fargo
Equal Weight
HC Wainwright & Co.
Neutral
BTIG
Neutral
Jefferies
Hold
Canaccord Genuity
Hold
Grade Summary
Price Target
Institutional Ownership
PENTWATER CAPITAL MANAGEMENT LP
5.3M Shares
$566.623M
HBK INVESTMENTS L P
4.264M Shares
$455.819M
BLACKROCK, INC.
3.827M Shares
$409.114M
FIL LTD
3.489M Shares
$372.956M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
3.384M Shares
$361.778M
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP
3.272M Shares
$349.769M
GLAZER CAPITAL, LLC
3.206M Shares
$342.74M
ABINGWORTH LLP
2.458M Shares
$262.731M
NEA MANAGEMENT COMPANY, LLC
2.253M Shares
$240.868M
GOLDMAN SACHS GROUP INC
1.935M Shares
$206.901M
BALYASNY ASSET MANAGEMENT L.P.
1.863M Shares
$199.219M
MILLENNIUM MANAGEMENT LLC
1.797M Shares
$192.089M
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC
1.785M Shares
$190.878M
MORGAN STANLEY
1.576M Shares
$168.48M
WHITEBOX ADVISORS LLC
1.567M Shares
$167.475M
JPMORGAN CHASE & CO
1.415M Shares
$151.253M
BARCLAYS PLC
1.394M Shares
$149.002M
VIVO CAPITAL, LLC
1.393M Shares
$148.972M
SYQUANT CAPITAL SAS
1.208M Shares
$129.181M
ALPINE ASSOCIATES MANAGEMENT INC.
1.157M Shares
$123.7M
Summary
Only Showing The Top 20